BK
Highly rated in
10
conditions
Highly rated in
10
conditions
Check Dr. Bruce R. Korf's experience treating your condition:
About Dr. Bruce R. Korf

Bruce Korf is a Pediatrics specialist and a Medical Genetics expert in Birmingham, Alabama. Korf has been practicing medicine for over 42 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1, Legius Syndrome, and RASopathies. He is licensed to treat patients in Alabama. Korf is currently accepting new patients.

His clinical research consists of co-authoring 139 peer reviewed articles and participating in 9 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Bruce R. Korf it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Bruce R. Korf accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter

Call to see if your plan is accepted.
Locations
720 20th St S, Kaul Human Genetics Building Room 230, Birmingham, AL 35233
Other Locations
2000 6th Ave S, Floor 1, Birmingham, AL 35233
1600 7th Ave S, Birmingham, AL 35233
Background & Education
Graduate Institution
Js Weill Medical College, Cornell University, 1980
Specialties
Pediatrics
Medical Genetics
Licenses
Clinical Genetics in AL
Hospital Affiliations
UAB Hospital
USA Health University Hospital
Childrens Of Alabama
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor AZD5153 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
View 6 Less Clinical Trials -

139 Total Publications



Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors